Century Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

De winst van Century Therapeutics zal naar verwachting dalen met 7.8% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 87.4% per jaar. De winst per aandeel zal naar verwachting groeien met 11.4% per jaar.

Belangrijke informatie

-7.8%

Groei van de winst

11.37%

Groei van de winst per aandeel

Biotechs winstgroei	29.0%
Inkomstengroei	87.4%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	17 Aug 2026

Recente toekomstige groei-updates

Recent updates

Analyse-artikel • Jul 16

Will Century Therapeutics (NASDAQ:IPSC) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, Century Therapeutics...

Analyse-artikel • Dec 17

There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise

Century Therapeutics, Inc. ( NASDAQ:IPSC ) shareholders have had their patience rewarded with a 32% share price jump in...

Analyse-artikel • Nov 30

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analyse-artikel • Oct 08

There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding

Century Therapeutics, Inc.'s ( NASDAQ:IPSC ) price-to-sales (or "P/S") ratio of 0.4x might make it look like a strong...

Seeking Alpha • Jun 20

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Summary Positive poster presentation results were released at ASCO 2024 from the phase 1 ELiPSE-1 study, which used CNTY-101 for the treatment of patients with relapsed/refractory CD19-positive non-Hodgkin lymphoma patients. The global non-Hodgkin Lymphoma market is expected to surge to $11 billion by 2029. Initiation of phase 1 CALiPSO-1 study, using CNTY-101 for patients with systemic lupus erythematosus, is expected in the 1st half of 2024; Data from this study is to be released 2nd half of 2024. A highly important thing about this company would be the Allo-Evasion technology incorporated into the iPSC-derived cell therapies, which not only improves the safety of patients but could mean improved responses. Read the full article on Seeking Alpha

Analyse-artikel • Mar 06

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Feb 01

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Summary Century Therapeutics is a biotech focused on developing engineered natural killer cells for cancer and rheumatologic conditions. Their first clinical product, CNTY-101, showed promising early data with a patient experiencing tumor shrinkage and a complete clinical response. However, Century Therapeutics has a limited cash position and needs to prove the efficacy of their therapies before being considered a confident investment. Read the full article on Seeking Alpha

Analyse-artikel • Oct 23

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Aug 25

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Century Therapeutics (NASDAQ:IPSC) will begin a phase 1 study of its allogeneic cell therapy CNTY-101 by the end of the year after receiving Investigational New Drug clearance from the US FDA. CNTY-101 is under investigation for relapsed or refractory CD19 positive B-cell malignancies. In the ELiPSE-1 study, all patients will receive an initial standard dose of conditioning chemotherapy. Schedule A consists of a single-dose escalation of CNTY-101 and subcutaneous IL-2. Schedule B will evaluate a three-dose schedule per cycle of CNTY-101. CNTY-101 is derived from a clonal induced pluripotent stem cell (iPSC) master cell bank that yields homogeneous product. Seeking Alpha's Quant Rating views Century (IPSC) as a hold with strong grades for profitability and momentum.

Winst- en omzetgroeiprognoses

NasdaqCM:IPSC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2028	N/A	-127	N/A	N/A	3
12/31/2027	N/A	-112	N/A	N/A	5
12/31/2026	N/A	-107	N/A	N/A	5
6/30/2026	N/A	-110	-88	-87	N/A
3/31/2026	N/A	-108	-95	-95	N/A
12/31/2025	109	-10	-105	-104	N/A
9/30/2025	113	-26	-113	-112	N/A
6/30/2025	114	-23	-115	-115	N/A
3/31/2025	115	-22	-115	-115	N/A
12/31/2024	7	-127	-110	-110	N/A
9/30/2024	3	-130	-113	-112	N/A
6/30/2024	2	-131	-103	-97	N/A
3/31/2024	1	-133	-99	-89	N/A
12/31/2023	2	-137	-102	-88	N/A
9/30/2023	2	-129	-104	-85	N/A
6/30/2023	5	-127	-121	-96	N/A
3/31/2023	6	-125	-133	-102	N/A
12/31/2022	5	-131	-17	14	N/A
9/30/2022	5	-127	-28	13	N/A
6/30/2022	2	-123	-34	13	N/A
3/31/2022	1	-115	-27	20	N/A
12/31/2021	N/A	-96	-134	-89	N/A
9/30/2021	N/A	-83	-108	-78	N/A
6/30/2021	N/A	-70	-82	-63	N/A
3/31/2021	N/A	-62	-66	-57	N/A
12/31/2020	N/A	-54	-51	-41	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat IPSC de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat IPSC de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat IPSC de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat IPSC volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat IPSC volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van IPSC naar verwachting over 3 jaar hoog zal zijn

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/09/14 15:36
Aandelenkoers aan het einde van de dag	2026/09/11 00:00
Inkomsten	2026/06/30
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Century Therapeutics, Inc. wordt gevolgd door 10 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Geoffrey Meacham	BofA Global Research
Chen Yang	BofA Global Research
William Maughan	Canaccord Genuity

Century Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 22% to US$3.67

Price target decreased by 11% to US$4.25

Consensus revenue estimates increase by 115%

Price target decreased by 8.3% to US$4.40

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 2,092%

Recent updates

Century Therapeutics Announces Appointment of Joseph Truitt to Board of Directors and Member of the Compensation Committee, Effective September 9, 2026

Will Century Therapeutics (NASDAQ:IPSC) Spend Its Cash Wisely?

Century Therapeutics Presents New Preclinical Data for CNTY-813 Islet Replacement Therapy At ADA 2026

New major risk - Financial position

Price target increased by 22% to US$3.67

Century Therapeutics, Inc., Annual General Meeting, Jun 11, 2026

Full year 2025 earnings: EPS exceeds analyst expectations

Century Therapeutics, Inc. announced that it has received $134.997458 million in funding from a group of investors

New major risk - Shareholder dilution

Century Therapeutics, Inc. Announces Resignation of Carlo Rizzuto as Director., Effective December 18, 2025

New minor risk - Share price stability

There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise

Century Therapeutics, Inc. Announces Board and Committee Appointments

We're Keeping An Eye On Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.37 loss in 3Q 2024)

Century Therapeutics, Inc. Announces New Beta Islet Program for Type 1 Diabetes

There Is A Reason Century Therapeutics, Inc.'s (NASDAQ:IPSC) Price Is Undemanding

Price target decreased by 11% to US$4.25

Nasdaq Grants Century Therapeutics an Additional 180 Calendar Day Period, or Until February 23, 2026, to Regain Compliance with the Bid Price Rule

Century Therapeutics, Inc. Announces Board and Committee Changes, Effective August 14, 2025

Century Therapeutics, Inc. Announces Departure of Morgan Conn, Ph.D. as the Chief Financial Officer, Effective July 11, 2025

Consensus revenue estimates increase by 115%

Price target decreased by 8.3% to US$4.40

New major risk - Financial position

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Century Therapeutics, Inc., Annual General Meeting, Jun 12, 2025

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 2,092%

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Century Therapeutics, Inc. Provides Business Update for Clinical Pipeline for CNTY-101

Century Therapeutics Receives A Notification Letter from the Nasdaq Stock Market Regarding Listing Rule 5450(a)(1)

Price target increased by 8.0% to US$9.00

Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-Derived iNK Cell Therapy Cnty-101 in B-Cell Mediated Autoimmune Diseases

New major risk - Shareholder dilution

New minor risk - Market cap size

Consensus revenue estimates increase by 23%

Price target decreased by 11% to US$10.40

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Market cap size

Century Therapeutics, Inc. Appoints Chad Cowan as Chief Scientific Officer, Effective October 1, 2024

Century Therapeutics, Inc. Appoints Morgan Conn as Chief Financial Officer, Effective October 14, 2024

Price target decreased by 7.1% to US$11.33

Consensus revenue estimates increase by 24%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Century Therapeutics Presents Interim Results from Phase 1 Elipse-1 Study At Asco 2024 Annual Meeting

Price target decreased by 18% to US$12.20

Consensus revenue estimates increase by 77%

Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.53 loss in 1Q 2023)

Century Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors

Century Therapeutics, Inc. (NasdaqGS:IPSC) agreed to acquire Clade Therapeutics, Inc. from Syncona Limited (LSE:SYNC) for $45 million.

Consensus revenue estimates decrease by 86%, EPS upgraded

Full year 2023 earnings released: US$2.30 loss per share (vs US$2.27 loss in FY 2022)

COO & Head of Early Development notifies of intention to sell stock

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

New minor risk - Share price stability

Consensus revenue estimates fall by 32%

Century Therapeutics, Inc. Announces Chief Executive Officer Changes

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

New major risk - Financial position

New minor risk - Market cap size

Consensus revenue estimates increase by 20%

Price target decreased by 19% to US$14.00